ENLV, IL0011319527

Enlivex randomizes 135 patients: trial progress tests Enlivex stock

Published on 10/29/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Topline six-month data are due by mid-2027. Enlivex stock costs EUR 2.35 on October 29, 2026, with 182 patients planned.

Trial progress and corporate reset

Enlivex reported that more than 70 percent of planned trial participants had been randomized on October 28, 2026.
The company implemented a 1-for-16 reverse share split effective October 27, 2026.
Enlivex announced a 60 percent workforce reduction on October 19, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex (ISIN IL0011319527) has randomized 135 patients in its Phase 2b Allocetra trial, the company said on October 28, 2026. The trial is designed for patients with moderate-to-severe age-related knee osteoarthritis, and topline six-month data are expected by mid-2027, according to GlobeNewswire.

Trial progress sets the next milestone

The enrollment figure places the study beyond 70 percent of its planned 182 participants. Sites in the United States, Denmark and Poland are recruiting, while the double-blind, placebo-controlled design measures pain, function, quality of life and mobility.

The program builds on three- and six-month Phase 1/2a results and received Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration in July 2026, according to the company release.

What does the reset mean?

Enlivex also faces a sharper capital and listing test. The company announced a 1-for-16 reverse share split effective October 27, 2026, after receiving a Nasdaq delisting notice tied to 30 sessions below the USD 1.00 minimum bid requirement, as reported by StockTitan.

On October 19, 2026, Enlivex said it would wind down non-clinical research and reduce its workforce by 60 percent, while management salaries would also be cut. The stated aim was to reduce cash burn and concentrate resources on the Phase 2b trial, according to the company investor page.

Dates that define the setup

The October 28 enrollment update is the latest of three company milestones. On October 19, Enlivex announced the 60 percent workforce reduction; on October 27, the reverse split became effective; on October 28, the company reported the 70 percent enrollment milestone. A scheduled earnings report is listed for November 13, 2026, while the trial's six-month data are expected by mid-2027.

Trading reference

Enlivex was trading at EUR 2.35 at Lang & Schwarz on October 29, 2026 at 12:50 p.m. CEST. The quote is supported by a market capitalization of USD 43.9 million as of October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of Enlivex stock.